Popular GH Peptide Protocols: Tesamorelin vs CJC-1295+Ipamorelin vs Sermorelin vs MK-677
If you're exploring growth hormone optimization, four approaches dominate the conversation: the FDA-approved Tesamorelin (the only GH secretagogue with a current US approval), the popular CJC-1295 + Ipamorelin injectable combination, historical Sermorelin monotherapy, and the oral alternative MK-677. They differ significantly in mechanism, evidence depth, convenience, side-effect profile, and cost. This comparison helps you understand the trade-offs between the four most-discussed protocols — not to prescribe one, but to inform conversations with a clinician about which fits your goals.
Four popular GH-optimization protocols, each with a different calling card. Tesamorelin is the only FDA-approved option (for HIV visceral fat) and has the strongest evidence. CJC-1295 + Ipamorelin is the mainstream biohacking stack — strong GH response, good tolerability. Sermorelin is the gentle, physiologic, long-track-record classic. MK-677 is the oral, cheapest option but comes with appetite and insulin-sensitivity trade-offs. Choice depends on whether you prioritize evidence, effect size, convenience, or cost.
Tesamorelin
An FDA-approved GHRH analog used to reduce visceral fat in HIV-associated lipodystrophy.
CJC-1295
A growth hormone-releasing hormone analog that stimulates the pituitary gland to produce more growth hormone.
Ipamorelin
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.
Sermorelin
A growth hormone-releasing hormone analog that was previously FDA-approved for diagnosing GH deficiency in children.
MK-677
An orally active growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1 release.
| Category | Tesamorelin | CJC-1295 + Ipamorelin | Sermorelin | MK-677 |
|---|---|---|---|---|
| Drug Class | Modified GHRH analog (44-aa) with trans-3-hexenoyl modification | GHRH analog (29-aa, with DAC) paired with ghrelin-mimetic (5-aa) | GHRH analog (29-aa, identical to endogenous GHRH 1-29) | Non-peptide small-molecule ghrelin receptor agonist |
| Primary Mechanism | Binds GHRH receptor on pituitary somatotrophs | GHRH receptor agonism (CJC) + ghrelin/GHSR agonism (Ipa) — complementary pathways for synergistic GH release | Binds GHRH receptor, mimics natural GHRH | Binds ghrelin/GHSR-1a orally |
| FDA Status | FDA-approved (Egrifta®) for HIV-associated lipodystrophy — only currently-approved GHRH analog | Not FDA-approved; available via licensed compounding pharmacies | Previously FDA-approved (Geref®); withdrawn in 2008 for commercial reasons, now compounded for off-label adult GH optimization | Not FDA-approved; development by Merck halted after CHF trial safety signal |
| Evidence Level | Strong — multiple Phase III RCTs, long-term post-marketing data | Moderate — human PK/PD studies for each peptide; no RCT of the specific combination but extensively observed clinically | Moderate — historical clinical trials for pediatric GH deficiency, smaller adult data | Moderate — human trials showing IGF-1 elevation; one CHF trial showed excess mortality |
| Administration | Subcutaneous injection, daily | Subcutaneous injection — CJC(DAC) 2–3×/week + Ipamorelin daily before bed (protocols vary) | Subcutaneous injection, daily (typically before bed) | Oral capsule or liquid, daily |
| Half-Life | ~26 minutes (requires daily dosing) | CJC with DAC: ~8 days; Ipamorelin: ~2 hours | 11–16 minutes (requires daily dosing) | ~24 hours (supports once-daily oral dosing) |
| GH Pulse Pattern | Amplifies natural pulsatile release | Sustained GHRH signal (CJC-DAC) + discrete Ipamorelin-induced pulses — synergistic and somewhat non-physiologic | Mimics natural pulsatile GH release closely | Sustained elevation of ghrelin signaling (less pulsatile) |
| Typical IGF-1 Response | Modest, sustained increase — dose-titrated in trials | Generally the largest IGF-1 elevation of the four options at typical protocols | Modest physiologic increase | Robust sustained IGF-1 increase |
| Effect on Cortisol/Prolactin | Minimal | Minimal — Ipamorelin's selectivity is the reason it's preferred over older GHRPs | Minimal | Mild cortisol and prolactin elevation reported in some studies |
| Effect on Appetite | Minimal | Mild transient hunger possible (ghrelin pathway via Ipa) | Minimal | Significant appetite stimulation — a frequent complaint and a reason MK-677 is not favored for body recomposition |
| Effect on Insulin Sensitivity | Generally neutral at therapeutic doses; monitoring advised | Neutral to mild impact | Neutral | May worsen insulin sensitivity over prolonged use — glucose monitoring advised |
| Key Clinical Benefits | Visceral fat reduction (proven in RCT), improved lipid profile, HIV-specific approval | Sustained GH/IGF-1 elevation, recovery support, sleep quality, body composition — the most popular biohacking GH protocol | Gentle physiologic GH restoration, anti-aging, sleep quality, decades of clinical precedent | Oral convenience, sustained IGF-1 elevation, widely accessible |
| Key Drawbacks | Expensive brand pricing; narrow approved indication; injection site reactions, arthralgia, edema | Combo adds cost and complexity; long-acting CJC-DAC creates non-pulsatile GH pattern some clinicians prefer to avoid — the no-DAC version preserves pulsatility but requires daily dosing | Very short half-life means strict daily dosing; not FDA-approved since 2008 | Appetite stimulation; insulin sensitivity concerns; halted CHF trial for excess mortality; weight gain common |
| Cost (Compounded, Monthly) | ~$500–1,500 (brand Egrifta); compounded versions significantly less | ~$150–350 for the combination | ~$100–250 | ~$50–150 (often the cheapest option) |
| Best Candidate Profile | Patients with visceral adiposity (especially HIV lipodystrophy) or those prioritizing FDA-backed GH therapy | Biohackers and performance-oriented users seeking maximum sustained GH/IGF-1 with injectable tolerability | Patients seeking physiologic, gentle GH restoration with a long clinical track record | Those prioritizing oral convenience and willing to accept appetite and metabolic trade-offs |
In depth
There is no single "best" option
GH peptide choice isn't a ranking exercise — each of these four compounds represents a distinct trade-off between evidence, effect size, convenience, and cost. The right answer depends on what you're optimizing for. Let's take each in turn.
Tesamorelin: the evidence leader
Tesamorelin is the only currently FDA-approved GH secretagogue, with Phase III evidence demonstrating visceral fat reduction and lipid improvements in HIV-associated lipodystrophy patients. That approval status is why it sits at the top of the regulatory trust ladder — but it's also what limits it. Tesamorelin requires daily subcutaneous injection, carries high brand pricing (compounded versions cost less but are harder to source), and has a narrow approved indication. For patients who specifically have visceral fat concerns or who need FDA-backed therapy for insurance or compliance reasons, Tesamorelin is the evidence leader and the most defensible choice.
CJC-1295 + Ipamorelin: the mainstream biohacking stack
The CJC-1295 + Ipamorelin combination is the most popular GH optimization protocol in the peptide space, and it got there for good reasons. The two peptides activate complementary pathways — CJC-1295 on the GHRH receptor, Ipamorelin on the ghrelin receptor — producing a synergistic GH response greater than either component alone. Ipamorelin's selectivity (minimal cortisol, prolactin, or appetite effects) makes it substantially better tolerated than older GHRPs like GHRP-6 and hexarelin. The combination is not FDA-approved but is routinely compounded with clinician oversight. The nuance worth knowing: CJC-1295 comes in two forms — with DAC (long-acting, weekly dosing, sustained GH exposure) and without DAC / Modified GRF 1-29 (short-acting, daily dosing, pulsatile GH pattern). Most mainstream protocols use the no-DAC version specifically because it preserves physiologic pulse patterns. If you're considering this combination, that with-or-without-DAC question is where the real decision lives.
Sermorelin: the physiologic classic
Sermorelin mimics endogenous GHRH almost exactly — it's effectively the natural sequence. That makes it the gentlest and most physiologic option, with the longest clinical track record of the injectables (it was FDA-approved as Geref until 2008, withdrawn for commercial rather than safety reasons, and is now available through compounding). The drawback is the 11–16 minute half-life — Sermorelin requires strict daily dosing before bed to align with the natural nighttime GH pulse. For users who want the most conservative, physiologically-closest GH-axis intervention, Sermorelin is the historical answer.
MK-677: the oral option with real trade-offs
MK-677 (ibutamoren) is oral and the cheapest, which makes it tempting especially for new users who don't want to inject. The downsides are real and shouldn't be glossed over. Appetite stimulation is pronounced enough to be a frequent reason people quit — the ghrelin-receptor mechanism that drives GH release also drives hunger, and the 24-hour half-life means sustained appetite drive. Insulin sensitivity can decline with chronic use. A congestive heart failure trial was halted for excess mortality in elderly patients — this was a specific frail population and the signal doesn't necessarily generalize to healthy users, but it's why Merck abandoned development. For body composition goals, MK-677's appetite stimulation can work against you enough to negate the GH benefit.
Practical decision tree
Most clinicians I've talked to follow roughly this logic: if proven efficacy and regulatory trust matter, start with Tesamorelin. If you want sustained GH elevation and are comfortable with injectable compounded therapy, CJC-1295 + Ipamorelin is the mainstream choice. If you want the gentlest, most physiologic option with the longest clinical history, Sermorelin. If oral convenience matters more than the metabolic trade-offs, MK-677 — but be honest with yourself about whether appetite stimulation will undo your body composition goals. All four require clinician supervision, IGF-1 monitoring, and should be paired with the foundational inputs (sleep, resistance training, nutrition) that drive endogenous GH rhythm. Peptide therapy doesn't substitute for those inputs — it amplifies whatever they're already doing.
These peptides are often used together. See our stack profiles for combination details.